Montelukast Teva (Montelukast Sodium)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, C4 and E4 from binding. This inhibition reduces bronchoconstriction, mucus production, and inflammatory cell recruitment, leading to improved airway function and reduced allergic symptoms.

The appropriate dose of Montelukast Teva is determined by the prescribing healthcare professional based on the patient’s age, indication and clinical response. Dosage may differ for asthma, allergic rhinitis or exercise‑induced bronchospasm, and should follow the prescriber’s instructions.

Safety data for Montelukast in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, so clinicians should weigh potential benefits against risks and discuss use with the patient. Breastfeeding mothers should also consult their healthcare provider.

To place an order, submit an enquiry on the Montelukast Teva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is especially useful for patients who prefer a tablet form or have aspirin‑exacerbated respiratory disease. While effective for maintenance, it is generally used in combination with inhaled therapies for optimal control.

Montelukast tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect them from moisture, excessive heat and direct sunlight to maintain product stability throughout its shelf life.

Montelukast Teva is taken orally as a tablet. The tablet should be swallowed whole with a glass of water, preferably at the same time each day. It can be taken with or without food, according to the prescriber’s guidance.

Serious adverse events include allergic reactions such as rash, angioedema or anaphylaxis, and neuropsychiatric effects like depression, mood swings or suicidal thoughts. Rare but severe skin reactions (Stevens‑Johnson syndrome) and significant liver enzyme elevations have also been reported. Patients should seek immediate medical attention if these occur.

Montelukast is contraindicated in individuals with known hypersensitivity to montelukast sodium or any of its excipients. Caution is advised for patients with severe hepatic impairment, active psychiatric disorders, or those taking interacting medications listed under major interactions.